NCT00581919 · ADVERSE EVENTS
Adverse events
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.
- Collection time frame
- Adverse Events were collected while subjects were receiving study treatment through 30 days post last dose of study treatment, up to 28 weeks.
- Other-event reporting threshold
- 5%
| Safety group | Serious events | Other events | Deaths |
|---|---|---|---|
| Bort, Dex, and Dox With ALCAR | 10 / 32 | 32 / 32 | Not reported / Not reported |
Serious adverse events
- organ System
- Vascular disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Thrombosis/embolism - DVT
- organ System
- General disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Fever (in the absence of neutropenia)
- organ System
- Nervous system disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 2
- num At Risk
- 32
- term
- CNS Hemorrhage/bleeding
- organ System
- Gastrointestinal disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Hemorrhage - Other, specify: GI-esophagus
- organ System
- Infections and infestations
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Febrile neutropenia - pneumonia
- organ System
- Infections and infestations
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 2
- num At Risk
- 32
- term
- Infection with unknown ANC
- organ System
- Infections and infestations
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Infection without Neutropenia
- organ System
- Infections and infestations
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Infection/Febrile Neutropenia
- organ System
- Infections and infestations
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Infection/Febrile Neutropenia - Other, specify: Normal ANC, Gr 1 or 2 neutrophils
- organ System
- Musculoskeletal and connective tissue disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Muscle weakness (not due to neuropathy)
- organ System
- Nervous system disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Neurology - Other, specify: encephalopathy
- organ System
- Nervous system disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Neurology - Other, specify: vocal cord paralysis
Other reported adverse events
- organ System
- Gastrointestinal disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 2
- num At Risk
- 32
- term
- abdominal pain
- organ System
- Investigations
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 6
- num At Risk
- 32
- term
- Alkaline phosphatase increased
- organ System
- Skin and subcutaneous tissue disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 3
- num At Risk
- 32
- term
- Alopecia
- organ System
- Blood and lymphatic system disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 21
- num At Risk
- 32
- term
- Anemia
- organ System
- Metabolism and nutrition disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 8
- num At Risk
- 32
- term
- Anorexia
- organ System
- Musculoskeletal and connective tissue disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 5
- num At Risk
- 32
- term
- back pain
- organ System
- Gastrointestinal disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 3
- num At Risk
- 32
- term
- Bloating
- organ System
- Musculoskeletal and connective tissue disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 7
- num At Risk
- 32
- term
- Bone pain
- organ System
- Eye disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 2
- num At Risk
- 32
- term
- Blurred vision
- organ System
- Injury, poisoning and procedural complications
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 5
- num At Risk
- 32
- term
- Bruising
- organ System
- Gastrointestinal disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 2
- num At Risk
- 32
- term
- Colitis
- organ System
- Psychiatric disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 2
- num At Risk
- 32
- term
- Confusion
Complete source fields
- event Groups
- description
- Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long
- id
- EG000
- other Num Affected
- 32
- other Num At Risk
- 32
- serious Num Affected
- 10
- serious Num At Risk
- 32
- title
- Bort, Dex, and Dox With ALCAR
- frequency Threshold
- 5
- other Events
- organ System
- Gastrointestinal disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 2
- num At Risk
- 32
- term
- abdominal pain
- organ System
- Investigations
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 6
- num At Risk
- 32
- term
- Alkaline phosphatase increased
- organ System
- Skin and subcutaneous tissue disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 3
- num At Risk
- 32
- term
- Alopecia
- organ System
- Blood and lymphatic system disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 21
- num At Risk
- 32
- term
- Anemia
- organ System
- Metabolism and nutrition disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 8
- num At Risk
- 32
- term
- Anorexia
- organ System
- Musculoskeletal and connective tissue disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 5
- num At Risk
- 32
- term
- back pain
- organ System
- Gastrointestinal disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 3
- num At Risk
- 32
- term
- Bloating
- organ System
- Musculoskeletal and connective tissue disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 7
- num At Risk
- 32
- term
- Bone pain
- organ System
- Eye disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 2
- num At Risk
- 32
- term
- Blurred vision
- organ System
- Injury, poisoning and procedural complications
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 5
- num At Risk
- 32
- term
- Bruising
- organ System
- Gastrointestinal disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 2
- num At Risk
- 32
- term
- Colitis
- organ System
- Psychiatric disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 2
- num At Risk
- 32
- term
- Confusion
- serious Events
- organ System
- Vascular disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Thrombosis/embolism - DVT
- organ System
- General disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Fever (in the absence of neutropenia)
- organ System
- Nervous system disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 2
- num At Risk
- 32
- term
- CNS Hemorrhage/bleeding
- organ System
- Gastrointestinal disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Hemorrhage - Other, specify: GI-esophagus
- organ System
- Infections and infestations
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Febrile neutropenia - pneumonia
- organ System
- Infections and infestations
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 2
- num At Risk
- 32
- term
- Infection with unknown ANC
- organ System
- Infections and infestations
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Infection without Neutropenia
- organ System
- Infections and infestations
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Infection/Febrile Neutropenia
- organ System
- Infections and infestations
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Infection/Febrile Neutropenia - Other, specify: Normal ANC, Gr 1 or 2 neutrophils
- organ System
- Musculoskeletal and connective tissue disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Muscle weakness (not due to neuropathy)
- organ System
- Nervous system disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Neurology - Other, specify: encephalopathy
- organ System
- Nervous system disorders
- source Vocabulary
- CTCAE version 3
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 32
- term
- Neurology - Other, specify: vocal cord paralysis
- time Frame
- Adverse Events were collected while subjects were receiving study treatment through 30 days post last dose of study treatment, up to 28 weeks.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle